Validation Of The Utility Of Newer Serum PSA Parameters For Prostate Cancer Detection

This review suggests that finasteride at 1 mg/day reduces PSA levels similarly to 5 mg/day, but differences in prostate dihydrotestosterone levels may affect prostate cancer diagnosis and prevention.

This study found that non-daily use of Dutasteride may be more cost-effective and associated with lower cancer incidence than daily use for patients seeking treatment for lower urinary tract symptoms.

This study observed that although 5-alpha-reductase inhibitors reduce PSA density in patients on active surveillance for prostate cancer, those who progress to more serious disease still show higher PSA densities, suggesting these inhibitors accentuate differences in clinically significant cases.

This study concludes that the accuracy of PSA testing for prostate cancer diagnosis is not only maintained but may be increased when used alongside 5-alpha reductase inhibitors like finasteride and dutasteride.

This review discusses how 5α-reductase inhibitors affect PSA levels in benign prostatic hyperplasia treatment and their role in prostate cancer screening, but reports no new clinical findings.